Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators - Full Text View

Purpose

Implantable cardioverter defibrillators (ICDs) have been developed to treat ventricular tachycardia or fibrillation (abnormal heart rhythms) by electrical shock or by pacing the heart. ICD therapy is established as highly effective for stopping life-threatening arrhythmias, but it does not preclude the use of anti-arrhythmic drugs for prevention and to decrease the frequency of ICD shocks.

The safety and effectiveness of oral azimilide dihydrochloride in reducing the frequency of ICD shocks has been investigated previously in a placebo-controlled study in patients with ICDs. These results need to be confirmed in this larger double-blind, placebo-controlled study with approximately 600 patients.

Condition	Intervention	Phase
Arrhythmia	Drug: Azimilide Dihydrochloride Drug: placebo	Phase III

Genetics Home Reference related topics:

Brugada syndrome short QT syndrome

MedlinePlus related topics:

Arrhythmia Pacemakers and Implantable Defibrillators

Drug Information available for:

Azimilide dihydrochloride Azimilide

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study

Official Title:	Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

Further study details as provided by Procter and Gamble:

Primary Outcome Measures:

Reducing the recurrence of all-cause shocks plus symptomatic ATP [ Time Frame: one year ] [ Designated as safety issue: No ]

Enrollment:	633
Study Start Date:	September 2001
Study Completion Date:	April 2004
Primary Completion Date:	April 2004 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Placebo Comparator Placebo tablets	Drug: placebo placebo tablet, once daily for one year
2: Experimental 75 mg azimilide	Drug: Azimilide Dihydrochloride 75 mg azimilide, once a day for one year
3: Experimental 125 mg azimilide	Drug: Azimilide Dihydrochloride 125 mg azimilide, once a day for one year

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Currently have an ICD implanted
Have had a documented episode of symptomatic arrhythmias that triggered a spontaneous ICD shock within 180 days of randomization.
If the ICD implant is recent, the patient must have had a documented episode of sustained arrhythmias or cardiac arrest within 42 days before implantation of the ICD

Exclusion criteria:

have severe heart failure
have a current diagnosis of psychosis
use illicit drugs
abuse alcohol
if female, are currently breast feeding, or plan to become pregnant during the study
are currently taking antiarrhythmic drugs or other drugs that prolong the QTc interval (a measurement taken from the ECG)
creatinine >2.5 mg/dL (221 mmol/L)
potassium <4.0 mEq or >5.5 mEq
have a neutrophil count (ANC) < 100 mL (low count of a type of white blood cell) at time of randomization
have 2 or more consecutive QTc values >440 msec

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035490

Show 142 Study Locations

Sponsors and Collaborators

Procter and Gamble

Investigators


Study Director:	Jose M Brum, MD	Procter and Gamble

More Information

Responsible Party:	Procter & Gamble Pharmaceuticals ( Jose Brum, MD )
Study ID Numbers:	2000098
First Received:	May 3, 2002
Last Updated:	February 13, 2008
ClinicalTrials.gov Identifier:	NCT00035490
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Heart Diseases

Azimilide

Arrhythmias, Cardiac

Additional relevant MeSH terms:

Membrane Transport Modulators

Pathologic Processes

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Calcium Channel Blockers

Cardiovascular Diseases

Cardiovascular Agents

Anti-Arrhythmia Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 24, 2008

Sponsored by:	Procter and Gamble
Information provided by:	Procter and Gamble
ClinicalTrials.gov Identifier:	NCT00035490